TVRD Cara Therapeutics Inc: Forward P/S Multiple

Corporate emblem and logo of Cara Pharma (TVRD)

Cara Therapeutics Inc (TVRD) research centers are developing innovative treatments for renal pruritus for patients with unmet therapeutic needs. The company's expected P/S ratio reflects a market premium trend, where 15.10 determines the latest valuation metric. The business operates on an asset-light model, outsourcing production to contract manufacturing organizations. The company is currently undergoing restructuring, focusing on identifying partners for asset licensing.

Cara Therapeutics - TVRD Forward P/S Multiple (period 07/04/2022 - 05/09/2026)

Metric breakdowns and analytics for Cara Therapeutics (TVRD)

- stock price and consensus target price:
Summary company analysis:Cara Therapeutics (TVRD)
Product sample of caratherapeutics.com

Monopolistic access to itch therapy via KOR activators makes Cara Therapeutics Inc (TVRD) revenue dependent on the adoption of clinical protocols in dialysis centers. The ratio of current market capitalization to expected sales provides a real-time assessment of market expectations for the expansion of this niche, while the forward P/S trend serves as an indicator of whether future growth is overpriced or a signal that the asset is undervalued.